MapLight Therapeutics, Inc. (MPLT) SEC Filings & Earnings Calls

Pre-revenue clinical-stage biotech with no approved products

“The Company is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders.” · word for word

Deepening operating losses and cash burn

“Net loss $ (60,192) for three months ended June 30, 2026 vs $ (29,845) for same period 2025; accumulated deficit $481.4 million as of June 30, 2026”

Dependence on future capital raises

“The Company's future viability is dependent on its ability to raise additional capital to finance its operations and pursue its business strategies.” · word for word

Clinical trial failure risk for remaining pipeline candidates

“ML-004 Phase 2 IRIS trial did not meet primary endpoint in social communication; company pausing further investment in preclinical and discovery-stage programs”

Dependence on single lead candidate ML-007C-MA

“Company is focusing resources on the advancement of ML-007C-MA, including pausing further investment in preclinical and discovery-stage programs” · word for word

Insider selling / loss of major holder

“Novo Holdings sells 1.6M shares, dropping below 5% threshold.”

Insider selling / loss of major holder

“Novo Holdings sells 1.6M shares, dropping below 5% threshold.”

Phase 3 trial failure risk

“Phase 2 results may not replicate in larger Phase 3 trials; historical high failure rate in schizophrenia drug development”

Competitive landscape risk

“First new mechanism (Cobenfy/muscarinic) approved in 2024; multiple competitors developing similar muscarinic agonists for schizophrenia”

Primary endpoint miss may limit commercial potential; further development uncertain.

“IRIS did not meet its primary endpoint in social communication deficits associated with ASD”

CFO departure due to HR violation may raise governance concerns.

“Mr. Setia’s separation was wholly unrelated to the Company’s financial or operating results, internal controls or clinical programs.”

Clinical trial failure risk

“We are a clinical-stage biopharmaceutical company with a limited operating history and no history of commercializing products.” · word for word

Need for additional capital

“We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed could cause us to delay, limit, reduce or terminate our product development.” · word for word

Clinical-stage biotech with no approved products; high dependency on trial outcomes

“MapLight is a clinical-stage biopharmaceutical company... no approved products”

Significant R&D spend increase may pressure cash runway if trials extend

“R&D expenses $53.7M in Q1 2026 vs $19.8M in Q1 2025”

Pre-revenue clinical-stage biotech; no approved products; high cash burn

“MapLight Therapeutics, Inc. ... clinical stage biopharmaceutical company”

Concentrated ownership by Catalyst4 (47.1%) limits minority influence

“Catalyst4, Inc. ... 47.1%”

Clinical Trial Failure Risk

“Clinical development is a lengthy and expensive process characterized by uncertain outcomes, with results of earlier studies and trials often failing to predict future trial results or results in other indications of a product candidate.” · word for word

Capital Requirement Risk

“We will require substantial additional capital to achieve our goals, and failure to obtain additional capital when needed or on acceptable terms, could cause us to delay, limit, reduce or terminate our product development or future commercialization efforts.” · word for word

Competitive Risk

“We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions and governmental agencies, as well as public and private research institutions.” · word for word

Regulatory Approval Risk

“Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize any product candidate in the U.S. or any other jurisdiction, and any such approval may be for a narrower indication than we seek.” · word for word

Clinical trial risk: Phase 2 results may not meet endpoints.

“Topline results from Phase 2 ZEPHYR and IRIS trials expected in Q3 2026; no data yet.”

Clinical trial timeline delay increases uncertainty around pipeline value.

“topline results from its ongoing Phase 2 ZEPHYR and IRIS clinical trials, which are now expected in the third quarter of 2026” · word for word

Clinical-stage company with no approved products or revenue; dependent on trial success.

“No revenue mentioned; all candidates in Phase 2 or preclinical.”

Long timeline to key data readouts (2026-2027) increases execution risk.

“Topline results from Phase 2 ZEPHYR trial expected in the second half of 2026; VISTA in second half of 2027”

Clinical-stage biotech risk

“Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization.” · word for word

Going concern risk mitigated by recent financing

“The Company has experienced negative operating cash flows since inception, and had an accumulated deficit of $281.0 million as of September 30, 2025. The Company expects to continue to generate operating losses for the foreseeable future.” · word for word